SolAeroMed is a company dedicated to the development of novel therapeutic strategies to treat obstructive lung diseases.

We aim to improve the quality and longevity of patients’ lives. This goal is being realized through the generation of quality biopharmaceutical technologies that are developed with “outside-the-box” thinking.  SolAeroMed aims to balance ethical and effective research and development with strategic partnering and a level of investment return to attract the resources required to develop our novel therapies.